Nanotein Exhibits at ISCT 2022
Curtis Hodge, CEO & Co-Founder of Nanotein, along with Zach Imam, Scientist II, presented Nanotein’s first exhibit at the ISCT 2022 conference in San Francisco, California. Throughout the conference from May 4th to 6th, they received lots of interest from potential beta-testers, collaborators, partners, and future customers!
Zach Imam, PhD
Zach is a scientific leader at Nanotein. His expertise in lipid nanoparticle development, protein biophysics, and rheological characterization is instrumental to Nanotein’s progress towards advancing their protein-derived nanoparticle for CAR-T cell activation and expansion. Zach received his PhD in Biomedical Engineering at the University of Texas at Austin and completed a Post-Doctoral Fellowship at […]
Team Outing
Members from Nanotein and their strategic partners, Polaris, met for a teambuilding lunch and photos! From left to right: Patrick Carney, Greg Hura, Zach Imam, Curtis Hodge, Chris Huxsoll, and Jose Ortiz.
Come Visit Our Exhibit at ISCT 2022 in SF!
Visit our booth to sign up for a FREE test kit of our Next-Gen Reagent!
Nanotein CEO Speaks at Biotech Planet International Conference
As an invited panel member, Curtis discussed the current state of biotech and its exciting future trajectory at Biotech Planet International Conference Dec. 12, 2021.
Nanotein Named Top 10 Biotech Startup of 2021
Read more Nanotein named a Top Ten Biotech Startup of 2021 by Life Sciences Review magazine
Nanotein Forms Strategic Partnership & Secures Funding
Nanotein and Polaris Group, a developer of novel treatments for cancer, announced they have entered into a strategic partnership to advance Nanotein’s protein-based solutions for superior cellular therapy manufacturing. Based on a proprietary platform technology, Nanotein’s first product is a superior T cell activation and expansion reagent for use in the biomanufacturing of CAR-T cell […]
Nanotein Chosen as a Top Emerging Biotech by QB3
“Eighty-five companies applied. From these, a judging panel drawn from industry and the investing community selected a cohort of 12: four “emerging,” or earlier-stage, startups, and eight who had advanced their technologies further along the path to market.” – QB3/Cision PR Newswire Nanotein Chosen as a Top Emerging Biotech by QB3 at Their Biotech/Biopharma […]
